Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature

Hardeep Chehal; Nikolaos G. Nikitakis; Mohammed N. Islam; Jason H. Goodchild; Lorenzo Mordini; Indraneel Bhattacharyya

Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature

Hardeep Chehal, Nikolaos G. Nikitakis, Mohammed N. Islam, Jason H. Goodchild, Lorenzo Mordini, Indraneel Bhattacharyya

Department of Diagnostic Sciences

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.

Original language	English (US)
Pages (from-to)	42-46
Number of pages	5
Journal	General dentistry
Volume	67
Issue number	1
State	Published - Jan 1 2019

All Science Journal Classification (ASJC) codes

Dentistry(all)

Fingerprint Dive into the research topics of 'Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature'. Together they form a unique fingerprint.

Cite this

@article{1d94c254f38d4b61bb968e1985a74ed2,

title = "Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature",

abstract = "Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.",

author = "Hardeep Chehal and Nikitakis, {Nikolaos G.} and Islam, {Mohammed N.} and Goodchild, {Jason H.} and Lorenzo Mordini and Indraneel Bhattacharyya",

year = "2019",

month = jan,

day = "1",

language = "English (US)",

volume = "67",

pages = "42--46",

journal = "General Dentistry",

issn = "0363-6771",

publisher = "Academy of General Dentistry",

number = "1",

}

TY - JOUR

T1 - Denosumab-related osteonecrosis of the jaw

T2 - a report of 2 cases and review of the literature

AU - Chehal, Hardeep

AU - Nikitakis, Nikolaos G.

AU - Islam, Mohammed N.

AU - Goodchild, Jason H.

AU - Mordini, Lorenzo

AU - Bhattacharyya, Indraneel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.

AB - Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85060032344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060032344&partnerID=8YFLogxK

M3 - Article

C2 - 30644830

AN - SCOPUS:85060032344

VL - 67

SP - 42

EP - 46

JO - General Dentistry

JF - General Dentistry

SN - 0363-6771

IS - 1

ER -